All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The United States Food & Drug Administration (FDA) has granted priority review to KTE-X19 for the treatment of patients with relapsed/refectory (R/R) mantle cell lymphoma (MCL). KTE-X19 is a chimeric antigen receptor (CAR) T-cell therapy that targets the CD19 antigen on the surface of lymphoma cells. The Biologics License Application for KTE-X19 was previously accepted by the FDA in December 2019 for R/R MCL, supported with data from the ZUMA-2 clinical trial. The FDA target action date is August 10, 2020.
Results from the phase II ZUMA-2 study in patients with R/R MCL were presented at the 61st American Society for Hematology (ASH) meeting in Orlando, US, available here. The full results from this study were recently been published in The New England Journal of Medicine.
In 60 efficacy evaluable patients in the primary analysis, the overall response rate was 93%, with a complete response rate of 67%. Safety results showed 15% of patients experienced Grade 3 or higher cytokine release syndrome, and 31% experienced neurotoxicity of any grade. Two Grade 5 events occurred. At a median follow-up of 12.3 months, 57% of patients were in remission. The 12-month estimated progression-free survival and overall survival were 61% and 83%, respectively.2
The European Medicines Agency (EMA) has also fully validated the marketing authorization application.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox